Medistim

Transaction in Own Shares • Apr 4, 2025

Medistim ASA – Status on share buyback

Medistim ASA – Status on share buyback

Oslo, 4th of April 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through 4th of April 2025, the Company purchased a total of 52,181 shares at an average price of NOK 183.8225 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

-----------------------------------------------------------------------------

Date / Aggregated daily volume (#shares) / Weighted average share price per day (NOK) / Total daily transaction value (NOK)

Date: 31 March 2025. Number of share: 3,000. Avg price: NOK 172.3090 per share

Date: 1 April 2025. Number of share: 2,000. Avg price: NOK 177.1560 per share

Date: 2 April 2025. Number of share: 2,000. Avg price: NOK 177.0038 per share

Date: 3 April 2025. Number of share: 2,000. Avg price: NOK 171.1533 per share

Date: 4 April 2025. Number of share: 638. Avg price: NOK 165.2147 per share

Total for this period:

9,638 shares purchased at average share price of NOK 172.5674 per share. Total transaction value was NOK 1,672,960.18.

Previously disclosed buybacks under the program:

42,543 shares purchased at average share price of NOK 186.1431 per share. Total transaction value was NOK 7,919,085.99

-----------------------------------------------------------------------------

The issuer’s holding of own shares:

Following the completion of the above transactions, Medistim owns a total of 75,298 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.411 % of Medistim’s share capital.

Appendix:

An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940

Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.